Clinical Trial Update: Immunogenicity and Safety Study of a Rapid Immunization Schedule With FSME-IMMUN 0.5 mL in Healthy Adults Aged 16 - 65 Years [Phase 4]

View source ↗

Summary

Phase 4 clinical trial evaluating the immunogenicity and safety of a rapid immunization schedule using FSME-Immun 0.5 mL in healthy adults aged 16-65; the study…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Tick-borne Encephalitis

Drugs mentioned

• FSME-IMMUN 0.5 mL

Snippet

Sponsor: Pfizer | Conditions: Encephalitis, Tick-borne | Phase 4 | Status: COMPLETED